Introduction {#Sec1}
============

Recent advances in cancer diagnosis and treatment over the past four decades have led to a significant increase of the overall survival rates in most cases of young women and men with cancer \[[@CR1]\]. Unfortunately, several malignancies occur at young age and necessitate aggressive anticancer therapies including alkylating chemotherapy and ionizing radiation that may lead to gonadotoxicity and future fertility loss as devastating side effects. Accordingly, the topic of how to prevent or mitigate the chemotherapy- and radiotherapy-induced gonadotoxicity, and subsequent fertility loss, has gained a growing importance \[[@CR2]--[@CR5]\]. Oncofertility is an interdisciplinary field at the intersection of oncology and reproductive medicine that aims to provide effective fertility options to young cancer patients through several fertility preservation and restoration strategies. The term "oncofertility" was coined in 2006 by the Oncofertility Consortium, Feinberg School of Medicine, Northwestern University, Chicago, IL, USA \[[@CR6]--[@CR8]\].

According to the most recent international guidelines, several established, debatable and experimental oncofertility options can be offered to young female and male patients with cancer in order to preserve and restore their fertility (Table [1](#Tab1){ref-type="table"}) \[[@CR9]--[@CR11]\]. Seldom, if ever, little data is available about oncofertility practice in limited resource settings. The recent Coronavirus (COVID-19) pandemic has resulted in a rapid cascade of unprecedented events around the globe including lockdowns and significant shortage of resources and services. The state of limited resource settings that COVID-19 pandemic has created globally should be taken seriously into account especially in healthcare sector. Thousands of patients worldwide have been affected due to cancelation or postponement of their medical treatments. In oncofertility, patients should receive their fertility preservation treatments urgently even in limited resource settings before initiation of anticancer therapy. Therefore, it is very crucial to learn more about oncofertility practice in limited resource settings such as in developing countries that suffer often from shortage of healthcare services provided to young patients with cancer.Table 1Fertility preservation options for patients undergoing gonadotoxic anticancer therapy**Oncofertility optionsFemale PatientsMale PatientsEstablished.** Embryo freezing**.** Egg freezing**.** Ovarian tissue freezing and autotransplantation**.** Sperm freezing**Debatable.** GnRH analogs and hormonal suppression**.** Oophoropexy**.** Gonadal shielding**.** Fractionated chemotherapy and radiotherapy**.** GnRH analogs and hormonal suppression**.** Gonadal shielding**.** Fractionated chemotherapy and radiotherapy**Experimental.** In vitro maturation of oocytes and vitrification**.** Artificial ovary**.** Stem cells**.** Neoadjuvant cytoprotective pharmacotherapy**.** Others**.** Testicular tissue freezing and autotransplantation**.** Stem cells**.** Neoadjuvant cytoprotective pharmacotherapy**.** Others

Over the past few years, the Oncofertility Consortium has studied oncofertility practice in developing countries. The Oncofertility Consortium had generated a survey within its Oncofertility Professional Engagement Network (OPEN) \[[@CR12]\] (Fig [1](#Fig1){ref-type="fig"}) to explore the barriers and opportunities associated with oncofertility practice in 14 developing countries in Africa, Latin America and Asia, including Egypt, Tunisia, Nigeria, South Africa, Brazil, Argentina, Chile, Peru, Panama, Mexico, Colombia, Guatemala, Saudi Arabia, and India. The survey questions were grouped into six categories: country profile, cancer care, fertility treatments, fertility preservation treatments, barriers to oncofertility, and opportunities of oncofertility. Responses from the surveyed centers in the 14 developing countries were collected, reviewed, and discussed. The results of the survey were published in two articles in the *Journal of Global Oncology*, one of the American Society of Clinical Oncology (ASCO) official journals \[[@CR13], [@CR14]\]. The surveyed centers from the 14 developing countries continue to experience common challenges such as shortage of healthcare services provided to young patients with cancer, lack of awareness among providers and patients, cultural and religious constraints, lack of insurance coverage, high out-of-pocket costs for patients, and lack of funding to support oncofertility programs. Despite these barriers, many opportunities exist and create a great potential for the future.Fig. 1Merger of American and global networks in to one unified network, the Oncofertility Professional Engagement Network (OPEN).

The limited resources in developing countries make their proper allocation of utmost necessity particularly in a complex medical field as oncofertility. As a practical approach, the Oncofertility Consortium has designed this new study: the Repro-Can-OPEN: Reproduction and Cancer in the Oncofertility Professional Engagement Network, in order to help bridge the gap between the international oncofertility programs and domestic standards in developing countries. Technically, Repro-Can-OPEN study aims to help developing countries install specific oncofertility programs for common cancers such as childhood cancer, breast cancer, and blood cancer according to their contemporary challenges and opportunities.

Methods {#Sec2}
=======

As a kickoff, the Oncofertility Consortium sent the Repro-Can-OPEN study questionnaire via email to the previously surveyed centers and experts in the 14 developing countries (Egypt, Tunisia, Nigeria, South Africa, Brazil, Argentina, Chile, Peru, Panama, Mexico, Colombia, Guatemala, Saudi Arabia, and India) to be proposed for childhood cancer, breast cancer and blood cancer. The Repro-Can-OPEN study questionnaire included questions on the availability of fertility preservation options provided to young female and male patients with cancer and whether these options are always, commonly, occasionally or rarely used (Tables [2](#Tab2){ref-type="table"}, [3](#Tab3){ref-type="table"}, [4](#Tab4){ref-type="table"} and [5](#Tab5){ref-type="table"}). The responses for childhood cancer, breast cancer, and blood cancer from the surveyed centers and experts in the 14 developing countries were collected, reviewed, and analyzed.Table 2Oncofertility Score calculation**Availability and Utilization of an oncofertility optionAvailable and always used for cancer patientsAvailable and commonly used for cancer patientsAvailable but occasionally used for cancer patientsAvailable but only used in research settings for cancer patientsNot available**Scale Symbol++++++++++-Actual Points (AP) (25 points per +)1007550250Maximal Points (MP) (100 points per ++++)100100100100100Oncofertility Score = AP/MP (%)100%75%50%25%0%Table 3Oncofertility Options and Scores (%) for Childhood Cancer in 14 developing countriesTable 4Oncofertility Options and Scores (%) for Breast Cancer in 14 developing countriesTable 5Oncofertility Options and Scores (%) for Blood Cancer in 14 developing countries

To analyze the collected data, our coauthor Dr. Salama from Northwestern University has developed a new scoring system called 'Oncofertility Score'. The 'Oncofertility Score, is a new diagnostic tool to measure the availability and utilization of an oncofertility option for cancer patients in a treating center, country, or group of countries. It is also a prognostic tool to follow up the development of oncofertility options and strategies provided to cancer patients over time. Oncofertility Score is calculated as a percentile ratio between the actual and maximal points of utilization that an oncofertility option might have (Table [2](#Tab2){ref-type="table"} & Fig [2](#Fig2){ref-type="fig"}). When a fertility preservation option is available and always used for cancer patients, it is given (Yes ++++) that weighs 100 actual points (25 points per each +). When a fertility preservation option is available and commonly used for cancer patients, it is given (Yes +++) that weighs 75 actual points (25 points per each +). When a fertility preservation option is available but occasionally used for cancer patients, it is given (Yes ++) that weighs 50 actual points (25 points per each +). When a fertility preservation option is available but only used in research settings for cancer patients, it is given (Yes +) that weighs 25 actual points (25 points per each +). When a fertility preservation option is not available, it is given (No) that weighs 0 actual points. The maximal points of utilization that an oncofertility option might have is 100 when it is available and always used for cancer patients and is given (Yes ++++), (25 points per each +).Fig. 2Oncofertility Score calculation

In this study with 14 developing countries, the Oncofertility Score is calculated as a percentile ratio between the total actual points and the total maximal points of utilization that an oncofertility option might have. The total actual points for an oncofertility option equal the sum of actual points for this option in all 14 countries. The total maximal points for an oncofertility option equal 100 points multiplied by 14 (number of countries in this study) resulting in 1400 points (Tables [3](#Tab3){ref-type="table"}, [4](#Tab4){ref-type="table"}, [5](#Tab5){ref-type="table"}).

Results {#Sec3}
=======

All surveyed centers and experts from the 14 developing countries (Egypt, Tunisia, Nigeria, South Africa, Brazil, Argentina, Chile, Peru, Panama, Mexico, Colombia, Guatemala, Saudi Arabia, and India) responded to all questions. Responses for childhood cancer, breast cancer, and blood cancer and their calculated oncofertility scores are listed in Tables [3](#Tab3){ref-type="table"}, [4](#Tab4){ref-type="table"}, [5](#Tab5){ref-type="table"}.

**The oncofertility scores (%) for options provided to children with cancer in the 14 developing countries were as following;** gonadal shielding in case of irradiation (67.85%), fractionation of chemo- and radiotherapy (60.71%), oophoropexy in case of pelvic irradiation (46.42%), GnRH analogs in case of old children (9-14 year) (33.92%), oocyte in vitro maturation (IVM) (28.57%), ovarian tissue freezing (25%), testicular tissue freezing (17.85%), neoadjuvant cytoprotective pharmacotherapy (3.57%), artificial ovary (1.78%), stem cells (1.78%) (Table [3](#Tab3){ref-type="table"} & Fig [3](#Fig3){ref-type="fig"}).Fig. 3Oncofertility Options and Scores (%) for Childhood Cancer in 14 developing countries

**The oncofertility scores (%) for options provided to female patients with breast cancer in the 14 developing countries were as following;** gonadal shielding in case of irradiation (62.5%), fractionation of chemo- and radiotherapy (62.5%), egg freezing (58.92%), embryo freezing (55.35%), GnRH analogs (55.35%), IVF/ICSI of frozen oocytes (55.35%), frozen embryo transfer (53.57%), ovarian tissue freezing (28.57%), oocyte in vitro maturation (IVM) (28.57%), autotransplantation of frozen ovarian tissue (19.64%), stem cells (3.57%), artificial ovary (1.78%), neoadjuvant cytoprotective pharmacotherapy (1.78%) (Table [4](#Tab4){ref-type="table"} & Fig [4](#Fig4){ref-type="fig"}).Fig. 4Oncofertility Options and Scores (%) for Breast Cancer in 14 developing countries

**The oncofertility scores (%) for options provided to patients with blood cancer in the 14 developing countries were as following;** gonadal shielding in case of irradiation (67.85%), sperm freezing (66.07%), fractionation of chemo- and radiotherapy (60.71%), egg freezing (58.92%), embryo freezing (55.35%), oophoropexy in case of pelvic irradiation (46.42%), GnRH analogs (33.92%), oocyte in vitro maturation (IVM) (28.57%), ovarian tissue freezing (25%), testicular tissue freezing (17.85%), neoadjuvant cytoprotective pharmacotherapy (3.57%), artificial ovary (1.78%), stem cells (1.78%) Fig [5](#Fig5){ref-type="fig"}.Fig. 5Oncofertility Options and Scores (%) for Blood Cancer in 14 developing countries

Discussion {#Sec4}
==========

Limited resource settings are not exclusive for developing countries as many other countries around the globe may relatively experience similar limiting conditions as happened recently with COVID-19 pandemic. Therefore, medical practice including oncofertility in limited resource settings has become a critical topic that every nation should take into account. Recently, a joint statement from the Oncofertility Consortium and the Alliance For Fertility Preservation on fertility preservation for patients receiving gonadotoxic therapies during the COVID-19 pandemic has been announced \[[@CR15]\]. The announcement came after the recommendations from the American Society for Reproductive Medicine (ASRM's COVID-19 Task Force) was distributed \[[@CR16]\], which suggests new IVF cycles should not be initiated at this time. Importantly, this pause in services does not apply to urgent fertility preservation for patients receiving gonadotoxic therapies, but in practicality, loss of general IVF may impact practices' standard operations. While clinicians and leaders in the fertility preservation community remain committed to handling these urgent cases, there are evolving geographic, legal, and practical constraints that may cause interruptions or delays. Understanding the resources necessary to provide this required medical option is important until the current pandemic resolves. Lessons learned will be valuable to future potential worldwide disruptions due to infectious diseases or other global crises.

Our Repro-Can-OPEN study showed different oncofertility domestic standards in developing countries under limited resource settings regarding childhood cancer, breast cancer, and blood cancer. Therefore, we will try here to use the results of our study to tailor and install plausible oncofertility programs for common cancers in limited resource settings in developing countries according to their contemporary challenges and opportunities (Table [6](#Tab6){ref-type="table"}).Table 6Plausible fertility preservation and restoration strategies for cancer patients in 14 developing countries**Cancer PatientsBefore Anticancer therapy**\
**(Fertility Preservation)During Anticancer therapy**\
**(Fertility Preservation)After Anticancer therapy (Fertility Restoration)Childhood Cancer**Leukemias, central nervous system cancers, and lymphoma**.** Freezing of gonadal tissue**.** In vitro maturation and vitrification of gametes (not yet reliable in children)**.** Oophoropexy in case of female pelvic radiation**.** Artificial gonads technology (not yet reliable)**.** Gonadal shielding**.** Fractionation of chemo- and radiotherapy**.** GnRH analogs in case of old child (9-14 year)**.** Neoadjuvant cytoprotective pharmacotherapy (not yet reliable)**.** IVF/ICSI of frozen gametes**.** Autotransplantation of frozen gonadal tissue (contraindicated in leukemia)**.** Stem cells (not yet reliable)**Breast Cancer**Patients with or without BRCA mutations**.** Egg freezing**.** Embryo freezing**.** Ovarian tissue freezing**.** In vitro maturation (IVM) of oocytes and vitrification**.** Artificial ovary technology (not yet reliable)**.** GnRH analogs**.** Fractionation of chemo- and radiotherapy**.** Gonadal shielding**.** Neoadjuvant cytoprotective pharmacotherapy (not yet reliable)**.** Intrauterine transfer of frozen embryo**.** IVF/ICSI of frozen oocytes**.** Autotransplantation of frozen ovarian tissue (contraindicated in BRCA mutations)**.** Stem cells (not yet reliable)**Blood Cancer**Leukemia (ALL, AML), and Lymphoma (NHL, HL)**.** Freezing of gametes**.** Freezing of gonadal tissue**.** In vitro maturation and vitrification of gametes**.** Oophoropexy in case of female pelvic radiation**.** Artificial gonads technology (not yet reliable)**.** GnRH analogs**.** Gonadal shielding**.** Fractionation of chemo- and radiotherapy**.** Neoadjuvant cytoprotective pharmacotherapy (not yet reliable)**.** Intrauterine transfer of frozen embryo**.** IVF/ICSI of frozen gametes**.** Autotransplantation of frozen gonadal tissue (contraindicated in leukemia)**.** Stem cells (not yet reliable)

Immediately after cancer diagnosis, we recommend early referrals of patients to oncofertility specialists in order to check the anticancer therapy plan and determine the related risk of gonadotoxicity and fertility loss. If the risk of gonadotoxicity and fertility loss is greater than 50%, an effective oncofertility strategy should be offered before, during and after anticancer therapy, after obtaining the informed consent from the patient or the legal guardians of a child. After complete cure from cancer, a new assessment of reproductive functions should be performed. If anticancer therapy induced gonadal dysfunction persists, fertility restoration may be achieved by using stored gametes or gonadal tissue \[[@CR17]--[@CR23]\].

Installing oncofertility programs for childhood cancer in 14 developing countries: {#Sec5}
==================================================================================

The common forms of childhood cancers that may require aggressive gonadotoxic anticancer therapy and hence necessitate prior fertility preservation measures are leukemia, central nervous system cancers, and lymphoma. **Before initiation of anticancer therapy**, freezing of prepubertal gonadal tissues (ovarian or testicular tissue) should be encouraged and attempted when possible. In vitro maturation and vitrification of gametes (oocytes or spermatozoa) and artificial gonads technology (ovary or testis) are still challenging in children and cannot be relied upon as effective oncofertility options in limited resource settings. Oophoropexy before female pelvis irradiation should be attempted when possible. **During anticancer therapy**, gonadal shielding in case of irradiation and fractionation of chemo- and radiotherapy should be attempted in all cases. GnRH analogs in case of old children (9-14 year) could be attempted while neoadjuvant cytoprotective pharmacotherapy is still very experimental in animal models and not yet reliable as an effective oncofertility option. **After anticancer therapy,** and when the patient becomes an adult and wishes for having children, fertility restoration may be achieved by using stored gametes. Autotransplantation of gonadal tissue can be offered to restore fertility but it should be contraindicated in leukemia due to possible contamination of gonadal tissue with leukemic cells. Stem cells reproductive technology is still very experimental and not yet reliable as an effective oncofertility option (Table [6](#Tab6){ref-type="table"}) \[[@CR8]--[@CR10], [@CR16]--[@CR22]\].

Installing oncofertility programs for breast cancer in 14 developing countries: {#Sec6}
===============================================================================

Breast cancer is the most common cancer in women during their reproductive years. Breast cancer may require aggressive gonadotoxic anticancer therapy and hence necessitate prior fertility preservation measures. Women with BRCA1 or BRCA2 mutations carry significant higher risks to develop breast and ovarian cancers, and they should receive oncofertility care as well. **Before initiation of anticancer therapy**, freezing of embryos or eggs should be attempted in all cases using tamoxifen, letrozole or random-start protocol for controlled ovarian stimulation to avoid high estradiol levels. Freezing of ovarian tissue should be attempted when possible. In vitro maturation and vitrification of oocytes could be attempted however artificial ovary technology is still challenging and cannot be relied upon as an effective oncofertility option in limited resource settings. **During anticancer therapy**, GnRH analogs and fractionation of chemo- and radiotherapy should be attempted in all cases. Gonadal shielding might be needed in case of combined irradiation to ovaries. Neoadjuvant cytoprotective pharmacotherapy is still very experimental in animal models and not yet reliable as an effective oncofertility option. **After anticancer therapy,** fertility restoration may be achieved by frozen embryo transfer, or in vitro fertilization of stored oocytes. Autotransplantation of ovarian tissue can be offered to restore fertility but it should be contraindicated in patients with BRCA mutations due to higher risks of developing ovarian cancer. Stem cells reproductive technology is still very experimental and not yet reliable as an effective oncofertility option (Table [6](#Tab6){ref-type="table"}) \[[@CR8]--[@CR10], [@CR16]--[@CR22]\].

Installing oncofertility programs for blood cancer in 14 developing countries: {#Sec7}
==============================================================================

The common forms of blood cancers that occur during the reproductive age and may require immediate aggressive gonadotoxic anticancer therapy and hence necessitate prior fertility preservation measures are acute lymphocytic leukemia (ALL), acute myeloid leukemia (AML), Non-Hodgkin lymphoma (NHL), and Hodgkin lymphoma (HL). **Before initiation of anticancer therapy**, freezing of embryos or gametes (oocytes or spermatozoa) should be attempted in all cases. Freezing of gonadal tissues (ovarian or testicular tissue) should be attempted when possible. In vitro maturation and vitrification of gametes could be attempted however artificial gonads technology is still challenging and cannot be relied upon as an effective oncofertility option in limited resource settings. Oophoropexy before female pelvis irradiation should be attempted when possible. **During anticancer therapy**, gonadal shielding in case of irradiation and fractionation of chemo- and radiotherapy should be attempted in all cases. GnRH analogs could be attempted while neoadjuvant cytoprotective pharmacotherapy is still very experimental in animal models and not yet reliable as an effective oncofertility option. **After anticancer therapy,** fertility restoration may be achieved by frozen embryo transfer, or in vitro fertilization of stored gametes. Autotransplantation of gonadal tissue can be offered to restore fertility but it should be contraindicated in leukemia due to possible contamination of gonadal tissue with leukemic cells. Stem cells reproductive technology is still very experimental and not yet reliable as an effective oncofertility option (Table [6](#Tab6){ref-type="table"}) \[[@CR8]--[@CR10], [@CR16]--[@CR22]\].

After installation of these specific oncofertility programs for common cancers in the 14 developing countries, we encourage all partners to use 'oncofertility score' as a prognostic tool to follow up the development of the new oncofertility programs and options provided to cancer patients over time. If oncofertility options are rejected, contraindicated, infeasible, unsuccessful or unavailable, adoption and third-party reproduction (sperm, egg, and embryo donation and surrogacy) can be offered as family building alternatives when possible \[[@CR5]\].

Conclusion {#Sec8}
==========

Medical practice in limited resource settings has become a critical topic that every nation should take into account especially after the global crisis of COVID-19 pandemic. Our Repro-Can-OPEN study showed different oncofertility domestic standards in limited resource settings in developing countries regarding childhood cancer, breast cancer, and blood cancer. Installation of specific oncofertility programs for common cancers such as childhood cancer, breast cancer, and blood cancer in developing countries according to their contemporary challenges and opportunities is highly recommended. Dissemination of this study results and recommendations will provide efficient oncofertility edification and modelling to pediatric, breast and hemato-oncologists in developing countries and help them offer the best care possible to their socio-economically disadvantaged patients. Meanwhile, the Oncofertility Consortium will continue to engage more stakeholders in developing countries to use the powerful networks in the United States and other developed countries to help build a sustainable oncofertility core competency worldwide.
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